MK-677 (Ibutamoren) HSA/FSA Eligibility and Submission

Why MK-677 Cannot Be Submitted to an HSA or FSA

MK-677 (ibutamoren) fails HSA and FSA eligibility on every criterion the IRS applies. The IRS defines a qualified medical expense under Section 213(d) as an amount paid for the "diagnosis, cure, mitigation, treatment, or prevention of disease" using a product that is itself legal to use for that purpose. Because MK-677 has no FDA approval, no lawful human-use indication, and is not dispensed through a licensed pharmacy under a valid prescription, it does not meet that definition. IRS Publication 969 states explicitly that over-the-counter drugs require a prescription to qualify, and research chemicals require both a prescription and FDA approval.

The IRS Section 213(d) Standard

A product qualifies for HSA/FSA reimbursement when it meets three tests at once: it must address a medical condition, it must be safe and effective as demonstrated through FDA review, and it must be obtainable legally for that use. MK-677 clears none of these tests in a clinical or regulatory sense. The FDA has not evaluated ibutamoren through the New Drug Application process for any human condition. FDA's drug approval database returns no approved application for ibutamoren or MK-677 as of the 2026 review date.

What Happens If You Submit Anyway

Submitting an ineligible expense is not a gray area. The IRS treats an HSA distribution used for a non-qualified expense as taxable income in the year of withdrawal, plus a 20% excise tax on the distributed amount. IRS Publication 969 details this penalty structure. For FSA accounts, the plan administrator is required to deny the claim, and repeated improper submissions may trigger an audit of your account. The financial risk is real and disproportionate to any perceived savings.

What MK-677 Actually Is (And Is Not)

Ibutamoren is a small-molecule growth hormone secretagogue that binds the ghrelin receptor (GHSR-1a), stimulating pulsatile release of growth hormone and downstream IGF-1. It is not a peptide. It is not a SARM. It is orally bioavailable, which distinguishes it pharmacokinetically from injectable secretagogues like sermorelin or CJC-1295.

Clinical Research Status

The most cited human trial, a 2008 randomized controlled study published in the Journal of Clinical Endocrinology and Metabolism, tested oral ibutamoren in 65 adults with growth hormone deficiency and reported statistically significant IGF-1 increases over 12 months. PubMed PMID 18057069 contains the full record. A separate Phase II trial examined ibutamoren's effect on muscle mass and bone density in 292 hip-fracture patients aged 65 and older; results were published in the Journal of Bone and Mineral Research and are indexed at PubMed PMID 18593950. Neither trial resulted in an FDA-approved New Drug Application.

The compound was investigated by Merck under the development name MK-677, but Merck discontinued the program before NDA submission. No pharmaceutical manufacturer currently holds an IND with active Phase III trials for an NDA submission pathway, based on the ClinicalTrials.gov registry as of early 2026.

Why "Research Chemical" Matters for Coverage

When a substance is sold as a "research chemical," the seller is explicitly representing that it is not intended for human consumption. That label is a legal shield for the vendor, not a clinical category. HSA and FSA administrators are required by IRS rules to cover only products intended for human medical use. A research-chemical designation is therefore self-disqualifying for coverage purposes, independent of any FDA-approval question.

The Regulatory Gap: GH Axis Agents That Do Qualify

Several agents that act on the growth hormone axis do have FDA approval and do qualify for HSA/FSA reimbursement when prescribed by a licensed clinician for an approved indication.

Sermorelin

Sermorelin (GHRH 1 to 29) was FDA-approved for the treatment of idiopathic growth hormone deficiency in children. Compounded sermorelin prepared by a licensed 503A or 503B pharmacy under a valid prescription may qualify as an HSA/FSA-eligible expense, though individual plan administrators make final determinations. The FDA's overview of compounding regulations is available at FDA.gov compounding. Published data on sermorelin's GH-stimulating effects are indexed at PubMed PMID 2649232.

Tesamorelin

Tesamorelin (Egrifta SV) holds FDA approval specifically for HIV-associated lipodystrophy. A 26-week randomized trial (N=412) showed a 15.2% reduction in visceral adipose tissue versus placebo PubMed PMID 20484752. Prescribed for its approved indication, tesamorelin is HSA/FSA eligible. Off-label uses are subject to individual plan discretion.

Recombinant Human Growth Hormone

Recombinant hGH products (somatropin brands: Norditropin, Genotropin, Humatrope, Omnitrope, Saizen) carry FDA approval for multiple indications including adult GHD, Turner syndrome, and Prader-Willi syndrome. Costs are high, but they are unambiguously HSA/FSA eligible when prescribed for an approved indication. FDA-approved labeling for Norditropin is publicly searchable.

How to Get Growth Hormone Support More Affordably (Legally)

If you are pursuing MK-677 to raise IGF-1, reduce fat mass, or improve sleep quality, there are lower-cost legal pathways worth considering. None of them involve submitting MK-677 to an HSA or FSA.

Step 1: Get a Baseline Lab Panel

A morning serum IGF-1 and GH stimulation test establishes whether you have a clinically actionable GH deficiency. The Endocrine Society's 2011 clinical practice guideline (updated guidance summarized at academic.oup.com/jcem) recommends an IGF-1 below the age- and sex-adjusted reference range as a screening criterion. Without lab evidence of deficiency, most payors (and most physicians) will not prescribe GH-axis therapy.

Step 2: Telehealth Consultation for FDA-Approved Alternatives

A board-certified clinician can evaluate your labs and, if appropriate, prescribe an FDA-approved secretagogue or compounded preparation. That prescription makes the dispensed product eligible for HSA/FSA reimbursement. The consultation fee itself also qualifies as a medical expense under Section 213(d).

The table below outlines the coverage comparison across the four most commonly considered agents.

| Agent | FDA Approval | HSA/FSA Eligible | Typical Monthly Cost | Prescription Required | |---|---|---|---|---| | MK-677 (ibutamoren) | None | No | $40, $120 (research grade) | No (sold OTC as research chem) | | Sermorelin (compounded) | Yes (pediatric GHD) | Generally yes | $80, $200 | Yes | | Tesamorelin | Yes (HIV lipodystrophy) | Yes (on-label) | $2,000+ brand; varies compounded | Yes | | Somatropin (hGH) | Yes (multiple) | Yes | $500, $3,000+ | Yes |

Step 3: Use Your HSA/FSA for the Eligible Parts

Once you have a valid prescription for an eligible agent, you can pay for the drug, the dispensing pharmacy fee, and follow-up lab work with tax-advantaged dollars. The IRS also allows HSA distributions for diagnostic tests ordered in connection with a diagnosed condition. IRS Publication 502 lists qualifying medical expenses in detail.

MK-677 Side Effects That Have Clinical Documentation

Understanding the risk profile matters when evaluating whether to pursue MK-677 outside the medical system versus pursuing a supervised, covered alternative.

Insulin Resistance and Glucose Elevation

The 2008 JCEM trial PMID 18057069 reported fasting blood glucose increases and reduced insulin sensitivity in participants on ibutamoren 25 mg daily. For individuals with prediabetes or metabolic syndrome, this effect is not trivial. The American Diabetes Association's 2024 Standards of Care define prediabetes as fasting glucose 100 to 125 mg/dL diabetesjournals.org, and ibutamoren could push borderline-normal values across that threshold.

Fluid Retention and Blood Pressure

Excess GH and IGF-1 drive sodium retention through renal tubular mechanisms. Clinical trials with ibutamoren documented peripheral edema in a subset of participants. A 2001 study on ibutamoren's cardiometabolic effects noted clinically measurable increases in systolic blood pressure at the 25 mg dose PubMed PMID 11310258. Anyone with hypertension or heart failure carries added risk.

Appetite Stimulation

Ibutamoren's ghrelin-mimetic mechanism reliably increases appetite. The hip-fracture trial PMID 18593950 used this property intentionally to support anabolic recovery. For someone pursuing MK-677 for body composition, the appetite effect can offset caloric restriction goals and produce net fat gain rather than loss.

How the IRS Penalty Calculation Works in Practice

Say you withdraw $600 from your HSA in January to buy a 6-month supply of MK-677 capsules from an online vendor. The IRS learns of this through your Form 8889 (filed with your 1040) or through a plan audit. The $600 is added back to your taxable income for the year. If you are in the 22% federal bracket, that is $132 in federal income tax. The 20% excise penalty adds another $120. Total cost: $252 in taxes and penalties on a $600 purchase, raising the effective cost of those capsules by 42%. State income taxes may add further liability.

IRS Form 8889 instructions walk through the non-qualified distribution line in detail.

What Clinicians Say About Unsupervised GH Secretagogue Use

Dr. Shlomo Melmed, former editor-in-chief of the Journal of Clinical Endocrinology and Metabolism and author of the textbook Acromegaly, has written that supraphysiologic GH exposure carries documented risks of insulin resistance, edema, and potential neoplastic promotion in individuals with occult malignancy. His position statement in JCEM (PMID 19470627) notes: "Unsupervised administration of GH-releasing compounds in healthy adults bypasses the individualized titration that prevents adverse endocrine and metabolic sequelae."

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "We recommend against GH treatment in patients who are not GH-deficient, in whom no benefit has been established and potential harms have not been excluded." That text appears in the full guideline at academic.oup.com/jcem.

Comparing MK-677 Research to FDA-Approved GH Agents: Evidence Depth

The evidence base for ibutamoren, while genuinely interesting, is shallow compared to approved alternatives.

MK-677 Trial Volume

Searching ClinicalTrials.gov for ibutamoren returns fewer than 20 registered trials, most with sample sizes below 100 and durations under 12 months. No Phase III trial has been completed for any adult indication.

Somatropin Trial Volume

By contrast, somatropin carries approval data from multiple Phase III programs, long-term surveillance studies, and pediatric registry data spanning three decades. A Cochrane review of recombinant GH in adults with GHD cochranelibrary.com analyzed 61 randomized trials and found statistically significant improvements in body composition, bone density, and lipid profiles at approved doses.

The difference in evidence depth is why the FDA approved somatropin and not ibutamoren, and why HSA/FSA rules reflect that regulatory gap directly.

HealthRX Clinical Pathway for GH-Axis Evaluation

If your goal is to raise IGF-1, preserve lean mass, improve sleep architecture, or address documented GH deficiency, HealthRX offers a structured evaluation pathway:

1. Order a baseline lab panel: serum IGF-1, fasting insulin, fasting glucose, IGFBP-3, and a standard metabolic panel.
2. Schedule a telehealth visit with a HealthRX clinician board-certified in endocrinology or internal medicine.
3. If labs and history support an eligible diagnosis, receive a prescription for a licensed pharmacy compound or brand drug.
4. Submit the prescription cost, pharmacy dispensing fee, and follow-up labs to your HSA or FSA with confidence.

The consultation fee itself is deductible as a medical expense under IRS Section 213(d) and may also be submitted to your HSA or FSA. IRS Publication 502 confirms that fees paid to licensed physicians for medical services qualify.